



JC02 Rec'd PCT/PTO 09 JUN 2005

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN THE APPLICATION OF:

ERIC DEGUYON TAYLOR

CASE NO.: BA9308USPCT

APPLICATION NO.: 10/518324 ✓

CONFIRMATION NO.: UNKNOWN

GROUP ART UNIT: UNKNOWN

EXAMINER: UNKNOWN

FILED: December 15, 2004

FOR: METHOD FOR PREPARING FUSED OXAZINONES

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In compliance with 37 C.F.R. §§1.97 and 1.98, Applicants bring to the attention of the U.S. Patent and Trademark Office the information listed on the enclosed PTO/SB/08A and/or PTO/SB/08B forms. A copy of the information, if required, is also enclosed. However, U.S. Application No. 10/518,325 is a national filing of WO 04/011453 and no additional copy of that specification is enclosed. A copy will be provided upon the Examiner's request. A copy of the PCT International Search Report is also enclosed.

Consideration of the information is requested under 37 C.F.R. § 1.56 and this information is submitted in accord with the provisions of §1.97(b): within three months of filing the national application under 37 C.F.R. §1.53(d), or entry into the national stage under 37 C.F.R. §1.491, or before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action on the merits after filing a Request for Continued Examination under 37 C.F.R. §1.114.

If this Information Disclosure Statement is filed under §1.97(b) but the mailing date hereof is after the mailing of a first Office Action on the merits, the

PTO is authorized to charge the fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. **04-1928** (E. I. du Pont de Nemours and Company) in order to complete the requirements for consideration of this Information Disclosure Statement.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "D. E. Heiser", written in a cursive style.

**DAVID E. HEISER**

Attorney for Applicants

Registration No.: 31,366


Telephone: (302) 892-1926

Facsimile: (302) 892-7949

Dated: June 6, 2005

T:\Patent Documents\Ag Products\BA-93xx\BA9308\IDS.doc





Substitute for form USPTO 10

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

### Complete if Known

Application Number	10/518324
Filing Date	December 15, 2004
First Named Inventor	ERIC DEGUYON TAYLOR
Group Art Unit	UNKNOWN
Examiner Name	UNKNOWN
Attorney Docket Number	BA9308USPCT

### OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	1	G.M. COPPOLA, THE CHEMISTRY OF 4H-3,1-BENZOXAZIN-4-ONES, J. HETEROCYCLIC CHEMISTRY, 1999, PAGES 563-588, VOL. 36	<input type="checkbox"/>
	2	JAKOBSEN ET. AL., INHIBITORS OF THE TISSUE FACTOR/FACTOR VIIA-INDUCED COAGULATION: SYNTHESIS AND IN VITRO EVALUATION OF NOVEL 2-ARYL SUBSTITUTED PYRIDO[3,4-D]-, PYRIDO [2,3-D][1,3], PYRAZINO[2,3-D][1,3]-, PYRIMIDO[4,5-D][1,3]-, PYRAZOLO[3,4-D]-, THIENO[3,2-D][1,3]-, AND THIENO[2,3-D][1,3]-OXAZIN-4-ONES, BIOORGANIC AND MEDICINAL CHEMISTRY, 2000, PAGES 2803-2812, VOL. 8	<input type="checkbox"/>
	3	JAKOBSEN ET. AL., INHIBITORS OF THE TISSUE FACTOR/FACTOR VIIA-INDUCED COAGULATION: SYNTHESIS AND IN VITRO EVALUATION OF NOVEL SPECIFIC 2-ARYL SUBSTITUTED 4H-3,1-BENZOXAZIN-4-ONES, BIOORGANIC AND MEDICINAL CHEMISTRY, PAGES 2095-2103, VOL. 8	<input type="checkbox"/>
	4	D.V. RAMANA ET. AL., FACILE SYNTHESIS OF 2-ARYL-4H-3,1-BENZOXAZIN-4-ONES, ORG. PREP. PROCED. INT., 1993, PAGES 588-590, 1993, VOL. 25	<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>


Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



1 of 2

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

### Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

on

JUNE 7, 2005

Date

Deborah M. Jones  
Signature

Deborah M. Jones

Typed or printed name of person signing Certificate

N/A

Registration Number, if applicable

302 992 4943

Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

10/518324

BA9308 US PCT - INFORMATION DISCLOSURE STATEMENT,  
PTO/SB/08A, PTO/SB/08B, REFERENCES